Proteasome– tag –
-
Molecular Glue Development Accelerates: Gluetacs and Degron Advance Key Programs in Targeted Protein Degradation
GlobeNewswire Global Overview The field of molecular glues, a powerful targeted protein degradation (TPD) modality, is rapidly expanding with two significant clinical advancements: Gluetacs Therapeutics has initiated a Phase II trial for... -
FDA Grants Accelerated Approval to Regeneron’s Bispecific Antibody Linvoseltamab (LYNOZYFIC) for Multiple Myeloma
International Myeloma Foundation USA Overview The International Myeloma Foundation reported that LYNOZYFIC (linvoseltamab-gcpt), a BCMA-CD3 bispecific antibody immunotherapy, received accelerated FDA approval in July 2025. This drug targ... -
ARNT Molecular Glue Degrader NEO-811 Initiates Phase 1/2 First-in-Human Study for Unresectable Clear Cell Renal Cell Carcinoma
Medical Oncology and Hematology Global Overview The NEO-811-101 study has commenced as an open-label, first-in-human, Phase 1/2 dose-escalation and expansion study of the ARNT molecular glue degrader, NEO-811. Targeting patients with loc... -
PROTAC Research Shifts to Structural Design, Oral Bioavailability, and AI-Driven Approaches: Bibliometric Analysis Reveals Emerging Frontiers and Pivotal Trial Era
PubMed USA Overview A bibliometric analysis of 2,630 PROTAC publications from 2001-2025 reveals a shift from early E3 ligase recruitment research to current hotspots including structural basis, ternary complex design, EGFR-directed degra... -
FDA Approval of First PROTAC Vepdegestrant Raises New Challenges in Targeted Protein Degradation Patent Strategy
Elkington and Fife UK Overview The FDA approval of vepdegestrant, the first PROTAC, marks a significant milestone for targeted protein degradation (TPD), bringing complex intellectual property considerations to the forefront. The unique ... -
First Half 2026 Sees 24 New Small-Molecule Approvals: Pioneering PROTAC Vepdegestrant and Oral GLP-1 Orforglipron Enter Market
Chemexpress China Overview Twenty-four small-molecule drugs received their first global approval in the first half of 2026, with 95.8% being oral dosage forms. Key highlights include the approval of the first commercial PROTAC, vepdegest... -
First PROTAC Approval Validates Targeted Protein Degradation as a Breakthrough Modality for Cancer Treatment
Converge Bio Unknown Overview The FDA approval of vepdegestrant, developed by Arvinas and Pfizer, signifies a major milestone for targeted protein degradation (TPD). This first-in-class PROTAC, approved for ER+/HER2-, ESR1-mutated advanc... -
FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation
Journal of Medicinal Chemistry - ACS Publications USA Overview On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated fo... -
FDA Approval a TPD Turning Point? Maria Soloveychik Cautions Single Molecule Success Doesn’t Guarantee All Targets
Drug Discovery Online USA Overview Maria Soloveychik acknowledges the FDA approval of a bivalent degrader as a crucial 'proof point' for the Targeted Protein Degradation (TPD) field but warns that this single molecular success does not n... -
bioRxiv Reports Novel AR Molecular Glue Degrader GZL626 Inhibits Prostate Cancer Cell Proliferation, Effective Against AR-V7
bioRxiv USA Overview A preprint published on bioRxiv reports a novel androgen receptor (AR) molecular glue degrader, GZL626. GZL626 was shown to induce proteasome-dependent degradation of both full-length AR and the AR splicing variant A...
